The binding of unfractionated heparin and low molecular weight heparin to thrombin-activated human endothelial cells

Thrombosis Research

Volumn 96, Issue 5, 1999, Pages 373-381

  Young, Edward ^a   Venner, Thomas ^a   Ribau, José ^a   Shaughnessy, Stephen ^a   Hirsh, Jack ^a   Podor, Thomas J ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Endothelial cells; Low molecular weight heparin; Thrombin; Unfractionated heparin

Indexed keywords

ENDOTHELIAL CELL GROWTH FACTOR; ENOXAPARIN; HEPARIN; THROMBIN;

ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG BINDING; DRUG CLEARANCE; ENDOTHELIUM CELL; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; UMBILICAL VEIN;

BINDING SITES; ENDOTHELIUM, VASCULAR; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; IODINE RADIOISOTOPES; MICROSCOPY, FLUORESCENCE; THROMBIN; UMBILICAL CORD;

EID: 0032763158     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(99)00125-5     Document Type: Article

References (32)

1. Hirsh J. Heparin. N Engl J Med. 324:1991;1565-1574.
2. Hirsh J., van Aken W.G., Gallus A.S., Dollery C.T., Cade J.F., Yung W.J. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation. 53:1976;691-695.
3. Hull R.D., Raskob G.E., Hirsh J., Jay R.M., LeClerc J.R., Geerts W.H., Rosenbloom D., Sackett D.L., Anderson C., Harrison L., Gent M. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med. 287:1972;324-327.
4. Young E., Cosmi B., Weitz J., Hirsh J. Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (Enoxaparin) to plasma proteins. Thromb Haemost. 70:1993;625-630.
5. Cosmi B., Fredenburgh J.C., Rischke J., Hirsh J., Young E., Weitz J.I. Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate. Circulation. 95:1997;118-124.
6. Lane D.A. Heparin binding and neutralizing proteins. Lane D.A., Lindahl U. Heparin, chemical and biological properties, clinical applications. 1989;363-391 CRC Press, Boca Raton, FL.
7. De Swart C.A.M., Nijmeijer B., Roelefs J.M.M., Sixma J.J. Kinetics of intravenously administered heparin in humans. Blood. 60:1982;1251-1258.
8. Boneu B., Caranobe C., Gabaig A.M., Dupouy D., Sie P., Buchanan M.R., Hirsh J. Evidence for a saturable mechanism of disappearance of standard heparin in rabbits. Thromb Res. 46:1987;835-844.
9. Boneu B., Caranobe C., Cadroy Y., Dol F., Gabaig A.M., Dupouy D., Sie P. Pharmacokinetic studies of standard unfractionated heparin, and low molecular weight heparin in the rabbit. Semin Thromb Haemost. 14:1988;18-27.
10. Boneu B., Buchanan M.R., Caranobe C., Gabaig A.M., Dupouy D., Sie P., Hirsh J. The disappearance of a low molecular weight heparin fraction (CY 216) differs from standard heparin in rabbits. Thromb Res. 46:1987;845-853.
11. van Rijn J.L.M.L., Trillou M., Mardiguian J., Tobelem G., Caen J. Selective binding of heparins to human endothelial cells. Implications for pharmacokinetics. Thromb Res. 45:1987;211-222.
12. Bârzu T., Molho P., Tobelem G., Petitou M., Caen J. Binding and endocytosis of heparin by human endothelial cells in culture. Biochim Biophys Acta. 845:1985;196-203.
13. Bârzu T., van Rijn J.L.M.L., Petitou M., Tobelem G., Caen J.P. Heparin degradation in the endothelial cells. Thromb Res. 47:1987;601-609.
14. Vannucchi S., Pasquali F., Chiarugi V., Ruggiero M. Internalization and metabolism of endogenous heparin by cultured endothelial cells. Biochem Biophys Res Commun. 140:1986;294-301.
15. Larnkjaer A., Østergaard P.B., Flodgaard H.J. Binding of low molecular weight heparin (Tinzaparin sodium) to bovine endothelial cells in vitro. Thromb Res. 75:1994;185-194.
16. Pearson J.D. The control of production and release of hemostatic factors in the endothelial cell. Baillière's Clin Haematol. 6:1993;629-651.
17. Toothill V.J., van Mourik J.A., Niewenhuis H.K., Metzellaar M.J., Pearson J.D. Characterization of the enhanced adhesion of neutrophil leukocytes to thrombin-stimulated endothelial cells. J Immunol. 145:1990;283-291.
18. de Romeuf C., Mazurier C. Heparin binding assay of von Willebrand factor (vWF) in plasma milieu - Evidence of the importance of the multimerization degree of vWF. Thromb Haemost. 69:1993;436-440.
19. Ehrich H.J., Gebbink R.K., Keijer J., Pannekoek H. Elucidation of structural requirements on plasminogen activator inhibitor 1 for binding to heparin. J Biol Chem. 267:1992;11606-11611.
20. Nelson R.M., Cecconi O., Roberts W.G., Aruffo A., Linhardt R.J., Bevilacqua M.P. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood. 82:1993;3253-3258.
21. Teien A.N., Lie M. Evaluation of an amidolytic heparin assay method. Increased sensitivity by adding purified antithrombin III Thromb Res. 10:1977;399-410.
22. Dawes J., Pepper D.S. Catabolism of low-dose heparin in man. Thromb Res. 14:1979;845-860.
23. Jaffé E.A., Nachman R.L., Becker C.G., Minick C.R. Culture of human endothelial cells derived from umbilical veins. Identification by morphological and immunological criteria J Clin Invest. 52:1973;2745-2756.
24. Hulme E.C., Birdsall N.J.M. Strategy and tactics in receptor-binding studies. Hulme E.C. Receptor-ligand interactions, a practical approach. 1992;63-176 Oxford University Press, New York.
25. 125I) heparin and low molecular weight heparin fraction CY 222 to endothelium in culture. Folia Haematol Leipzig. 114:1987;429-436.
26. Young E., Wells P., Holloway S., Weitz J., Hirsh J. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost. 71:1994;300-304.
27. Leung L., Saigo K., Grant D. Heparin binds to human monocytes and modulates their procoagulant activities and secretory phenotypes. Effect of histidine-rich glycoprotein. Blood. 73:1989;177-184.
28. Leculier C., Benzerara O., Couprie N., Francina A., Lasne Y., Archimbaud E., Fiere D. Specific binding between neutrophils and heparin. Br J Haematol. 81:1992;81-85.
29. Weitz J.I., Hudoba M., Massel D., Maraganore J., Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 86:1990;385-391.
30. Young E., Prins M., Levine M.N., Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost. 67:1992;639-643.
31. Chiu H.M., van Aken W.G., Hirsh J., Regoeczi E., Horner A.A. Increased heparin clearance in experimental pulmonary embolism. J Lab Clin Med. 90:1977;204-215.
32. Weitz J.I. Low molecular weight heparin. N Engl J Med. 337:1997;688-698.